Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Castellum Aktiebolag completes the offer to the shareholders of Kungsleden Aktiebolag and thereby becomes the owner of 91.9 percent of the shares in Kungsleden Aktiebolag

On 2 August 2021, Castellum Aktiebolag ("Castellum") announced a recommended public offer to the shareholders of Kungsleden Aktiebolag ("Kungsleden") to acquire all shares in Kungsleden (the "Offer"). On 1 November 2021, Castellum announced that the acceptance period was extended until 9 November 2021.The extended acceptance period for the Offer ended on 9 November 2021. Today, Castellum announces that: · All conditions for completion of the Offer have been fulfilled. Accordingly, the Offer is declared unconditional in all respects and Castellum will complete the acquisition of the

Changes in Kamux Corporation’s Management Team and in Swedish Management

Kamux Corporation       Stock Exchange Release       November 10, 2021 at 9:45 (EET) Changes in Kamux Corporation’s Management Team and in Swedish Management Tommi Iiskonmäki, Kamux’s Swedish Country Director and Member of the Group Management Team, has announced to leave the company and take up new responsibilities outside the company. He will continue in the company until February 9, 2022 but as of today, in other duties. And as of today, he will no longer be a member of the Kamux Group Management Team. We thank Tommi Iiskonmäki for his contribution to the development of Kamux.

EQT strengthens position in healthcare investments by joining forces with LSP

EQT AB (publ) today announces the signing of an agreement (the “Transaction”) to acquire LSP (“Life Sciences Partners” or the “Company”), a leading European life sciences venture capital firm with approximately EUR 2.2 billion of assets under management (AUM) and a team of 34 professionals. · LSP will strengthen EQT’s position as one of the leading and most active private markets investors in the healthcare sector  · LSP’s highly experienced team will complement EQT’s existing knowledge base within life sciences and expand EQT’s ability to support companies at the forefront of

TORM plc Third Quarter Report 2021

“The market for refined oil is at present negatively impacted by the restricted crude supply not meeting demand, thereby drawing onshore stocks resulting in stock levels that are below five-year lows in several regions. This imbalance has led to historically low product tanker freight rates in the third quarter of 2021, resulting in an EBITDA of USD 30.4m and a loss before tax of USD -14.1m,” says Executive Director Jacob Meldgaard and adds: “In these challenging times, TORM continues a relentless focus on operational efficiency while maintaining a solid liquidity and capital structure.”

Invitation to presentation of Embracer Group’s Q2 report

Embracer Group hereby invites you to a presentation in connection to the publication of the interim report for the second quarter, the period July-September 2021. The report will be published at 06.00 (CEST) on November 17th and available as of this time at: www.embracer.com.The presentation will be held in English by CEO Lars Wingefors and CFO Johan Ekström, and afterwards a Q&A session will follow, led by analyst Oscar Erixon from Carnegie. Covid-19Embracer Group safeguards stakeholders' health and strives to help limit the spread of the coronavirus, as well as comply with applicable

Scania and SCA develop first 80 tonne electric timber truck

In another step towards a fossil-free society, SCA and Scania are together developing the first electric timber truck with a technical capability of up to 80 tonnes total weight. The vehicle is a sustainable transport solution enabled through another close cooperation between Scania and a progressive customer.It is possible to drive longer distances with heavy electric transports. Scania and SCA are proving that with a new battery electric vehicle capable of total weights of up to 64 tonnes on public roads and 80 tonnes on private roads. The electric truck will transport timber in the

Interim Report 1 January - 30 September 2021

The quarter was characterised by the opening of many of our businesses as restrictions were gradually eased. By way of comparison, we can report that sales for the quarter increased markedly year-over-year, but were still 40% lower than the same quarter in 2019. Happily, the restrictions in Sweden, Norway and Denmark were entirely removed on 29 September, and since then all operations have been able to open fully again after most of them had been forced to remain closed for 18 months. This means we can now offer shows, musicals, theatres and events without restrictions to audience size, and

Mackmyra launches peated deluxe version of a celebrated classic

Mackmyra is introducing a new addition to its exclusive Moment series. A nod to the original distillery at Mackmyra Bruk but also a steppingstone towards the future. Moment Brukswhisky DLX II is a single malt whisky that is aged solely at Bodås mine since distillation. This new addition is an elevated and luxury version of Mackmyras classic Brukswhisky and is available in a limited series released on the 17th of November.This expression answers the question of how Mackmyra Brukswhisky tastes after further maturation and using a smoky recipe. The Whisky has gone through an intriguing

INTERIM REPORT Period from January 2021 to September 2021

Lune Group OY incl subsidiary is consolidated in the group from 2020-06-03 Peptonic Medical AB (publ) org nr 556776-3064 (www.spotlightstockmarket.com ticker: PMED)Group, Lune Group OY incl subsidiary is included from 2020-06-03 2021 THIRD QUARTER (Jul-Sep) · Net sales of products KSEK 7,234 (9,260) · Gross profit KSEK 4,493 (6,228), Gross margin 62% (67%) · Operating loss KSEK -9,853 (-7,264)  · Loss per share SEK -0.05 (-0.04) 2021 FIRST NINE MONTHS (Jan-Sep) · Net sales of products KSEK 28,949 (13,732) · Gross profit KSEK 16,060 (9,608), Gross margin 55%

Rejlers wins rail jobs and grows in infrastructure

Rejlers has won several assignments that strengthen the company's position as a technology consultant in the rail sector. The initiative is part of Rejlers’ growth strategy and goal to increase the proportion of assignments that contribute to a sustainable society.Common to the assignments is to contribute to reduced environmental impact through electrified transport and an improved working environment. The assignments span several technical disciplines within Rejlers. “We collaborate within Rejlers' different areas of expertise to best meet needs and challenges, which strengthens our

Gasum Group Q3 2021 – Surge in gas prices affected the company’s result

Key financial indicators January 1 to September 30, 2021.· Group revenue totaled €811.6 million (1–9/2020: €448.9 million). · The Group’s operating result was ‑€5.0 million (1–9/2020: €12.8 million). · Balance sheet total came to €1,972.4 million (30.9.2020: €1,256.1 million). · The Group’s equity ratio was 15.0% (30.9.2020: 38.8%). · The company appointed CFO Kai Laitinen as interim CEO. Gasum Group Interim CEO Kai Laitinen comments on Q3 and the year to date 2021:  “Q3 of the year saw a very sharp rise in gas prices. This affected the development of company’s revenue and

FluoGuide selects lung cancer as the next indication for FG001 and will initiate phase II trial in the beginning of 2022

Copenhagen, Denmark, 10 November 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) is delighted to announce that the company has selected lung cancer as the second clinical indication for FG001.The clinical trial will be conducted at Rigshospitalet in Denmark during 2022.FluoGuide now broadens the clinical potential for fluorescence-guided cancer surgery with FG001 to include the first prevalent indication – lung cancer. FluoGuide will initiate the phase II trial in collaboration with Department of Cardiothoracic at Rigshospitalet in Denmark. As announced in October 2021, FG001 was safe

Interim Financial Report Q1-03 2021: best-ever nine-month results with strong organic growth and solid earnings margins

Today, the Board of Directors of H+H International A/S (hereinafter referred to as “H+H” or “the Group”) has adopted the Interim Financial Report for the first three quarters of 2021 (“Q1-Q3 2021”). CEO Michael T. Andersen quote “I am pleased with the continued strong organic growth and the solid earnings margins reported for the third quarter, marking the best-ever nine-month results for H+H. I am also very pleased with the two acquisitions announced since the last earnings report. These will further strengthen our German footprint and add important capacity to our German production

First in the world – Atria communicates the carbon footprint on the packaging of its pork products

Atria is a pioneer in sustainability in its industry and now also discloses the carbon footprint of its pork products on its consumer packaging. Earlier this year, Atria introduced carbon footprint labelling on all chicken products. The label on the packaging indicates the climate impact of the entire production chain of the product in terms of carbon dioxide equivalents. The carbon footprint is calculated and reported per packaged product (kg CO\2\e / product). Carbon footprint labelled pork products are now available in stores all over Finland. The calculation covers approximately half

InDex Pharmaceuticals Holding AB (publ) announces Nomination Committee for the 2022 Annual General Meeting

November 10, 2021 – InDex Pharmaceuticals Holding AB (publ) today announced the composition of the Nomination Committee for the 2022 Annual General Meeting. The responsibility of the Nomination Committee is to present to the 2022 Annual General Meeting proposals regarding election of the Chairman of the Board and other members of the Board, fees and any other remuneration to the members of the Board as well as election and remuneration of the auditors.The Nomination Committee for the 2022 Annual General Meeting of InDex Pharmaceuticals Holding AB (publ) consists of: · Karl Tobieson,

Financial Report 3rd quarter for DOF ASA

The Group's revenue for 3rd quarter (management reporting) totals NOK 2,052 million (NOK 2,027 million) and EBITDA totals NOK 865 million (NOK  879 million). Including in EBITDA is gain on sale of vessels of NOK 44 million (NOK 12 million). The operating profit (EBIT) is NOK 488 million (NOK -46 million), of which depreciation and impairment totals NOK 377 million (NOK 925 million). Net profit is NOK -128 million (NOK - 406 million). Key information: Operations:•    Average utilisation of the fleet 83% (71%)•    High utilisation in all segments•    Good performance from the

Interim report 1 January – 30 September 2021

third QUARTER (1 July – 30 September 2021) · Net sales for the quarter amounted to MSEK 117 (24). · Operating profit/loss before depreciation and amortisation (EBITDA) totalled MSEK 76 (0). · Operating profit/loss (EBIT) was MSEK 61 (-16). · Comparable profit/loss before tax amounted to MSEK 57 (-32) and recognised profit/loss before tax was MSEK 54 (-32). · Profit/loss after tax totalled MSEK 54 (-32), corresponding to SEK 1.41 (-0.92) per share before and SEK -1.27 (-0.92) per share after dilution. · Operating cash flow was MSEK -1 (49) and cash flow after investments

Interim Report for 3rd Quarter 2021

Q3: Increase in Customer Deposits of almost 6%. Q1-Q3: All-Time High in Revenues in the first 9 months of 2021Key Facts for the 3[rd] Quarter 2021 (1[st] July 2021 – 30[th] September 2021) Customer deposits increased almost 6% All figures are compared to the same quarter last year if not explicitly stated otherwise · Revenues decreased by 0.31% to €10,132,959 (€10,164,280). · EBIT decreased by 38.30% to €2,112,089 (€3,423,011). · EBIT margin of 20.84% (33.68%). · Customer deposits increased by 5.89% to €21,941,853 (€20,721,369). · 54,046 new registered customers (57,

SAS increases the number of flights to the US as demand for travel rises

As a direct result of the US now opening to more visitors, demand for travel is rising sharply. SAS is now updating its traffic program and increasing the number of flights to and from the US.Flight bookings with SAS to the US over Christmas and New Year have increased significantly. SAS is offering up to 100 flights per week during the Christmas and New Year period to and from Scandinavia. “It is very gratifying that we can increase the number of flights and offer our customers the chance to finally be able to travel again and experience the other side of the Atlantic, and meet with

Irisity AB (publ) delivers a third quarter with continued strong growth.

The CEO comments on the third quarter: Net sales during the period amounted to SEK 17.2 million (7.0) and capitalized work SEK 3.5 million (2.5). EBITDA SEK 1.1 million (-3.2) and profit after tax SEK -2.4 million (-6.5). The gross margin was 59.1 percent (48.4). Cash and cash equivalents at the end of the period SEK 163.4 million (25.8). We report the last quarter before the acquisition of Agent Vi with a strong sales development within all customer segments. Net sales increased by 146 percent and monthly recurring revenue (MRR) by 40 percent on a quarterly basis. Gross margin,

Tradedoubler Interim Report January - September 2021

The third quarter July – September 2021 · Total revenue amounted to SEK 317 M (285) an increase of 11% or 12% adjusted for changes in exchange rates compared to the same period last year. · Gross profit was SEK 67 M (59), an increase of 13% or 14% adjusted for changes in exchange rates. Gross margin was 21.0% (20.7). · Operating costs excluding depreciation and change related items were SEK 52 M (42), an increase of 24% or 25% adjusted for changes in exchange rates.  · EBITDA amounted to SEK 13 M (16). Adjusted for change related items, EBITDA was SEK 15 M (17). ·

Quickbit interim report for the first quarter of 2021/2022

Sales increased 80% year-on-year, primarily through more merchants joining but also due to a slight recovery following the impact of the preceding year’s revenue restructuring on sales. Merchants numbered 67 at the quarter’s end, up from 29 at the same date last year. Investments in consumer products continued and the Quickbit App launched in the Swedish market in August.First quarter, July–September 2021 in summary · Net sales totalled €97.1 million (54.0), up 80% year-on-year. · Gross profit amounted to €3.6 million (2.3) with a gross margin of 3.7% (4.3). · Adjusted EBITDA was

Interim report January-September 2021: Continued strong organic growth, improved gross margin and supply chain challenges

Third quarter: July-September 2021 · Net sales amounted to MSEK 315.6 (80.6), which corresponds to an increase of 292% (121) compared to the corresponding period previous year. Organic growth amounted to 59% (49). Adjusted for sales of non-recurring pandemic-related hygiene products the previous year, the quarter’s organic growth was 80%. · EBITDA amounted to MSEK -33.8 (-5.6), corresponding to a margin of -10.7% (-6.9). The operating profit during the quarter was affected by acquisition costs totalling MSEK 4.7 (9.8). Other costs affecting comparability include implementation

Telia Company launches 5G SA core network in Finland – the first commercially available 5G SA network in the Nordic and Baltic region

· First commercially available 5G standalone (SA) core network launched in the Nordics and Baltics · Brings lower latency and network slicing capabilites, supporting enterprise customers’ need for business model innovation; sets the foundation for new innovative consumer applications · Telia will offer residential customers in Finland wireless broadband connections with guaranteed speeds based on 5G SA technology · Builds on Telia Company’s strategy to inspire its customers, connect everyone, transform to digital, and deliver sustainably as the leading operator in the region

There are no items matching the current filter
There are no more items matching the current filter
Back to top